Drug Profile
huMNC2-CAR44 T cells
Alternative Names: CAR T therapeutics - Minerva; huMNC2-CAR44 T cells - Minerva Biotechnologies; huMNC2-scFv-CAR T cells; MUC1*-targeting CAR T cellsLatest Information Update: 03 Aug 2022
Price :
$50
*
At a glance
- Originator Minerva Biotechnologies
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Breast cancer
- Preclinical Solid tumours
Most Recent Events
- 03 Aug 2022 huMNC2-CAR44 T cells is still in preclinical development for Solid tumours in USA (Minerva Biotechnologies pipeline, August 2022)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 22 Jun 2020 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 111th Annual Meeting of the American Association for Cancer Research - II (AACR-2020)